Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Revenio Group Oyj in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $34.80.
Current Consensus is
The current consensus among 2 polled investment analysts is to moderate buy stock in Revenio Group Oyj. This Moderate Buy consensus rating has held steady for over two years.
Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging and DRSplus, a device for detection of diabetic retinopathy; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.